Keybank National Association OH Sells 12,771 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Keybank National Association OH cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 314,900 shares of the medical research company's stock after selling 12,771 shares during the quarter. Keybank National Association OH owned about 0.08% of Thermo Fisher Scientific worth $156,694,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pictet North America Advisors SA boosted its holdings in shares of Thermo Fisher Scientific by 2.0% during the 1st quarter. Pictet North America Advisors SA now owns 8,989 shares of the medical research company's stock valued at $4,473,000 after buying an additional 177 shares in the last quarter. Phraction Management LLC grew its holdings in Thermo Fisher Scientific by 7.2% in the first quarter. Phraction Management LLC now owns 30,164 shares of the medical research company's stock worth $15,010,000 after purchasing an additional 2,037 shares during the period. DAVENPORT & Co LLC increased its stake in shares of Thermo Fisher Scientific by 13.7% during the first quarter. DAVENPORT & Co LLC now owns 4,668 shares of the medical research company's stock valued at $2,323,000 after purchasing an additional 562 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Thermo Fisher Scientific by 3.1% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 57,329 shares of the medical research company's stock worth $28,527,000 after purchasing an additional 1,741 shares in the last quarter. Finally, Clear Creek Financial Management LLC increased its position in Thermo Fisher Scientific by 12.5% during the 1st quarter. Clear Creek Financial Management LLC now owns 2,368 shares of the medical research company's stock valued at $1,179,000 after buying an additional 264 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Barclays cut their price target on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Royal Bank Of Canada decreased their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $0.05 during trading on Thursday, reaching $427.71. The stock had a trading volume of 739,719 shares, compared to its average volume of 1,965,058. The stock's 50 day moving average is $409.06 and its two-hundred day moving average is $481.30. The firm has a market cap of $161.46 billion, a PE ratio of 25.08, a PEG ratio of 2.24 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm's revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.11 earnings per share. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.